Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTX-2001 alone and with darolutamide in mCRPC
NCT07103018Phase 1Recruiting
- Sponsor
- K36 Therapeutics
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KTX-2001 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by K36 Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 21 days and Maximum Tolerated Dose at 21 days. Started Nov 2025; status: recruiting.
02
Drugs
KTX-2001
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07103018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07103018.